Skip to main content
TRDA
NASDAQ Life Sciences

Entrada Therapeutics Reports Significant 2025 Net Loss Amidst R&D Expansion and Workforce Reduction

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$11.98
Mkt Cap
$457.866M
52W Low
$4.93
52W High
$13.17
52W Position info
143% above low
Off High info
9.0% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

TRDA has more than doubled off its 52-week low of $4.93.

Summary

Entrada Therapeutics reported a substantial net loss of $143.8 million for 2025, a significant decline from 2024's net income, primarily due to decreased collaboration revenue and increased R&D expenses, alongside a 20% workforce reduction. Despite these financial challenges, the company maintains a cash runway into Q3 2027 and continues to advance multiple clinical and preclinical programs.


Key Events · Earnings and Guidance · TRDA

  • Financial Performance Shift

    Reported a net loss of $143.8 million for the year ended December 31, 2025, a significant decline from the net income of $65.6 million in 2024.

  • Collaboration Revenue Decline

    Collaboration revenue decreased significantly to $25.4 million in 2025 from $210.8 million in 2024, primarily due to the substantial completion of research plan activities for the partnered VX-670 program.

  • Workforce Reduction Implemented

    Approved a strategic plan in April 2025 that included a 20% workforce reduction, incurring $1.9 million in related charges.

  • Solid Cash Runway Maintained

    Reported cash, cash equivalents, and marketable securities of $295.7 million as of December 31, 2025, projected to fund operations into the third quarter of 2027.


Analysis · TRDA · Life Sciences

The 2025 annual report reveals a challenging financial year for Entrada Therapeutics, marked by a substantial net loss and a significant drop in collaboration revenue following the completion of key research activities for its partnered candidate VX-670. The 20% workforce reduction further underscores efforts to manage costs amidst these changes. However, the company's robust cash position, providing a runway into Q3 2027, is a critical positive for a clinical-stage biotech. The continued advancement of its DMD pipeline, including the initiation of higher dose cohorts for ENTR-601-44 and patient dosing for ENTR-601-45, along with the introduction of a new ocular clinical candidate, demonstrates ongoing progress in its core therapeutic areas. The establishment of a $150 million ATM program offers a flexible mechanism for future capital raises, which will be essential as R&D expenses are expected to increase with pipeline progression. Investors should monitor the clinical trial readouts in 2026 and the company's ability to manage its burn rate and secure additional non-dilutive funding.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TRDA was trading at $11.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $457.9M. The 52-week trading range was $4.93 to $13.17. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TRDA - Latest Insights

TRDA
Nov 18, 2026, 3:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.96
Real-time Price: $4.64 info
Change: -$0.320 (-6%) info
Market Cap: $181.658M info
TRDA
Nov 05, 2026, 3:28 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $4.59
Real-time Price: $4.64 info
Change: +$0.050 (+1%) info
Market Cap: $181.658M info
TRDA
Oct 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.03
Real-time Price: $4.64 info
Change: -$0.390 (-8%) info
Market Cap: $181.658M info
TRDA
Aug 05, 2026, 7:11 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $4.64 info
Change: -$2.61 (-36%) info
Market Cap: $181.658M info
TRDA
Aug 05, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $4.64 info
Change: -$2.61 (-36%) info
Market Cap: $181.658M info